CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BGNE

Zanubrutinib

Phase 3
BeiGene, Ltd. (BGNE)

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jun '27
BGNEPhase 2

Zanubrutinib Phase 2 Est. Readout

Zanubrutinib
Jun 2027~STALE
CT.gov
00%
Oct '26
BGNEPhase 2

Zanubrutinib Phase 2 Est. Readout

Zanubrutinib
Oct 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Refractory Mantle Cell Lymphoma

View Full Landscape
Drug Information

Target Indication

Refractory Mantle Cell Lymphoma

Clinical Trial

NCT03206970

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.